Lazydays (GORV) Q1 2025 Earnings Call May 15, 2025 08:30 AM ET Company Participants Jeff Needles - CFORon Fleming - Interim CEOAmber Dillard - COO Operator and welcome to the Lazydays RV Holdings First Quarter twenty twenty five Conference Call. At this time, all participants are on a listen only mode. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host Mr. Jeff Needles, Chief Financial Officer. Thank you. Please go ahead. Jeff Needles Thank you, operator, and welc ...

NICE (NICE) Q1 2025 Earnings Call May 15, 2025 08:30 AM ET Speaker0 Welcome to the NICE Conference Call discussing First Quarter twenty twenty five Results, and thank you all for holding. All participants are at present in a listen only mode. Following management's formal presentation, instructions will be given for the question and answer session. As a reminder, this conference is being recorded, 05/15/2025. I would now like to turn this call over to Mr. Marty Cohen, VP of Investor Relations at NICE. Pleas ...

Financial Data and Key Metrics Changes - The company reported a net income of $18.6 million for the first quarter, resulting in a positive primary EPS of $1.28 and a positive diluted EPS of $0.34 [23][24]. - A significant liability reduction of approximately $25 million was achieved, primarily from a reduction in convertible notes and accrued expenses [19][20]. - The company ended the quarter with $40 million in pro forma cash, extending its runway well into 2026 [11]. Business Line Data and Key Metrics Changes - Lucid, the company's diagnostic subsidiary, reported revenue of $800,000 with a test volume of 3,034, meeting the target range [10]. - Verus has restarted the development of a key implantable physiologic monitor after securing financing [12][14]. - The incubator PMX is focused on advancing technologies, particularly the PortIO device, with ongoing discussions with strategic partners [8][14]. Market Data and Key Metrics Changes - The company is seeing momentum in new sales channels, particularly in concierge medicine and employer market contracts, which are expected to impact revenue in the second half of the year [11][12]. - The company is awaiting a response from the MolDX program regarding Medicare coverage for EsoGuard, which is anticipated to be imminent [12]. Company Strategy and Development Direction - The company aims to diversify into the biopharma space, leveraging its infrastructure and management services model to capitalize on early-stage assets in oncology and cardiometabolic areas [9][39]. - The strategic focus includes expanding partnerships and exploring new assets that fit within the shared services model [10][39]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning and ability to execute its strategic vision, highlighting the potential value creation from Lucid and Verus [51][52]. - The company is optimistic about leveraging its model and infrastructure to pursue significant opportunities in the near future [52][53]. Other Important Information - The company has deconsolidated Lucid from its financial statements, which will affect year-over-year comparisons in the upcoming quarters [16][22]. - PAVmed remains the largest shareholder of Lucid, holding approximately 29% of the common shares outstanding [20]. Q&A Session Summary Question: Feedback from the pilot program - Management received excellent feedback from the pilot program, with all pre-specified performance metrics met and enthusiasm from academic medical centers [31][32]. Question: Exclusive rights to the platform - There are local rights for advancing the platform, but no exclusivity that limits broader commercialization efforts [34][35]. Question: Rationale for expanding into biopharma - The company is leveraging its adjusted corporate structure and management services to explore opportunities in biopharma, particularly in early-stage assets that require clinical research [39][40]. Question: Impact of market volatility on capital raising - Management indicated that market volatility has not significantly affected their ability to raise capital, with successful financing in the first quarter [47][48].

Financial Data and Key Metrics Changes - The company improved its liquidity to $72 million at the end of 2024, including an $18 million credit facility, following two successful securities offerings that raised approximately $60 million in gross proceeds [12] - The GAAP net loss for the full year was $111.8 million, a slight improvement from $114.2 million in 2023, primarily due to lower engineering and R&D expenses [13] - On a non-GAAP basis, the net loss improved to $70.3 million from $98.3 million in 2023, driven by reductions in engineering and R&D expenses [14] Business Line Data and Key Metrics Changes - The company achieved significant milestones in technology, including the first federal motor vehicle safety standard certification for a full by-wire vehicle in the US and the completion of the first autonomous drive on an active runway with Airbus [5][8] - The launch of ReAI Cloud in collaboration with Geotab opened new software revenue opportunities, indicating a shift towards a software-driven business model [5] Market Data and Key Metrics Changes - The company reported close to $1 billion in reservations, which includes binding orders and capacity reservations, indicating strong demand for its technology despite the temporary pause in production [34] - The current US tariffs and trade policies have significantly impacted the supply chain, affecting the company's ability to execute its original production plans [7][8] Company Strategy and Development Direction - The company is focusing on a software-first approach, transitioning towards a subscription-based revenue model and licensing its technology to OEMs and technology companies [10][20] - A strategic decision was made to temporarily pause production to address uncertainties in the macroeconomic environment and tariffs, while prioritizing software development [10][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's technology and its ability to adapt to market conditions, emphasizing the importance of preserving cash for future flexibility [21] - The company remains optimistic about the demand for its software-defined vehicle technology, which is seen as a cornerstone for future mobility [9][22] Other Important Information - The company plans to significantly reduce monthly operational expenses, targeting a reduction from $5-6 million to $3-4 million by the end of the year [30] - There is substantial doubt about the company's ability to continue as a going concern for the next twelve months, prompting plans for cost reductions and restructuring [17] Q&A Session Summary Question: Can you talk about the conversion of the MOU to a definitive agreement? - Management indicated that there is currently no change in the timeline for the MOU and that payments have already started being received for services delivered [27][28] Question: What is the actual cash balance at the end of the quarter excluding the credit facility? - The cash balance was reported at $61 million excluding the credit facility [29] Question: Can you discuss the cash burn and headcount at the end of the quarter? - The anticipated operating expenses are expected to be between $5-6 million a month, with plans to reduce this to $3-4 million by year-end [30][31] Question: Have there been any cancellations in reservations due to the production pause? - Management noted that customer interest in the product has increased, and they believe there is strong demand for their technology despite the production pause [34]

Financial Data and Key Metrics Changes - HIFU revenues for Q1 2025 were EUR 6.2 million, an increase of 6.8% compared to EUR 5.8 million in Q1 2024 [11][24] - Total worldwide revenue for Q1 2025 was EUR 13.6 million, a decrease of 9.1% from EUR 14.9 million in the same period in 2024 [12][25] - Gross profit for Q1 2025 was EUR 5.7 million, down from EUR 6.4 million in Q1 2024, with a gross profit margin of 42% compared to 42.8% year-over-year [25][26] - Net loss for Q1 2025 was EUR 7.1 million or EUR 0.19 per diluted share, compared to a net loss of EUR 4.5 million or EUR 0.12 per diluted share in the prior year [27] Business Line Data and Key Metrics Changes - The company placed nine Focal One systems in Q1 2025, a record for any first quarter, including six cash sales and three operating leases [4][6] - U.S. procedures grew approximately 4% over Q1 2024, despite longer review and approval times for Medicare Advantage patients [12][13] Market Data and Key Metrics Changes - Four cash sales of Focal One systems were completed outside the U.S. in Q1 2025, indicating growing international demand [11] - The company noted that over half of the National Comprehensive Cancer Network (NCCN) member institutions now have access to the Focal One platform [10] Company Strategy and Development Direction - The company aims to become the global leader in HIFU focal therapy, focusing on growing its core HIFU business and expanding clinical data support [4][6] - The launch of the new Focal One I robotic HIFU system is expected to enhance technological leadership and meet future needs of surgeons [22][31] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in the payer landscape, particularly with Medicare Advantage plans, but noted progress in appeals and approvals [35][38] - The company reiterated its 2025 revenue guidance, expecting HIFU revenue growth between 16% and 25% year-over-year, while non-core segments are projected to decline [30][41] Other Important Information - The company received CE Mark approval for the treatment of deep infiltrating endometriosis, marking a significant regulatory milestone [14][15] - A landmark remote transatlantic Focal One robotic HIFU procedure was successfully conducted, showcasing technological advancements [17][18] Q&A Session Summary Question: Changes in payer landscape and procedure approvals - Management noted that the trends are primarily relevant to Medicare Advantage Plan patients, with ongoing efforts to improve market access and reimbursement [35][36] Question: Continued challenges in Q2 and approval processes - Management confirmed that while there is a risk of denials, notable progress in appeals is being made, with a majority of appeals resulting in approvals [38][39] Question: HIFU sales growth guidance assumptions - The guidance incorporates expected procedure growth and assumes that payer challenges may recede in the second half of the year [40][41] Question: Marketing plans for endometriosis after CE Mark approval - The company is in a controlled market entry phase in CE Mark countries and is preparing for broader launch based on clinical data [44][46]

Lifeward (LFWD) Q1 2025 Earnings Call May 15, 2025 08:30 AM ET Speaker0 Good day, and welcome to the Q1 twenty twenty five LifeForward, Inc. Earnings Conference Call. All participants will be in listen only mode. Please note this event is being recorded. I would now like to turn the conference over to Mike Lawless, Chief Financial Officer. Please go ahead. Speaker1 Thank you, Cindy. Good morning and welcome to LifeWorks first quarter twenty twenty five earnings call. I'm Mike Laulis, LifeWorks Chief Financi ...

Financial Data and Key Metrics Changes - The company ended the quarter with a cash balance of $3.2 million, with cash used in operations for the three months ended March 31, 2025, at $1.3 million, reduced from $2.5 million for the same period in 2024 [22] - The net loss for the first quarter of 2025 was $2.8 million or $0.70 per share, compared to a net loss of $3.8 million or $1.10 per share for the first quarter of 2024 [22] Business Line Data and Key Metrics Changes - The company made significant progress in clinical trials, particularly in solid tumors, with new data presented at the AACR IO conference showing immune activation and early clinical activity in patients with second-line gastric cancer [6][11] - The company is advancing its INKT cell therapies in multiple areas, including solid tumors and immune-related diseases, with a focus on acute respiratory distress syndrome (ARDS) and graft versus host disease (GVHD) [16][19] Market Data and Key Metrics Changes - The company is engaging in confidential discussions for proposals that could extend its runway and accelerate its impact in oncology and immunology [10] - The company has observed promising survival rates exceeding 70% in critically ill ventilated patients with ARDS, indicating the potential to change treatment paradigms [16] Company Strategy and Development Direction - The company is focused on advancing its INKT platform in oncology and immunology, with plans to initiate a phase one trial for GVHD and continue developing its CAR NKT and TCR NKT therapies [19][20] - The company aims to diversify capital, reduce dilution, and accelerate development through external partnerships, reflecting strong external conviction in the value of its INKT platform [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the regulatory path forward, particularly with the FDA's increased receptivity to novel immune-based approaches [17] - The company is committed to advancing its programs rapidly, guided by scientific conviction and a mandate to bring transformative immune-based therapies to patients in need [20] Other Important Information - The company has been able to reduce its operating cash burn by about 47% year on year, preserving its ability to invest in core programs [6] - The company expects to receive formal funding from the National Institute of Allergy and Infectious Diseases (NIAID) by June, which would provide critical non-dilutive funding [20] Q&A Session Summary Question: Regarding the testicular cancer patient, how long after treatment was the complete response observed? - The complete response was formally designated at month 24 after the initial treatment of AGENT-797, with disease stabilization observed during the 12-month follow-up period [25][27] Question: Is the company still on track for initial efficacy data in the phase two gastric trial in the second half of this year? - The company is on target to present initial efficacy data by the end of this year, with ongoing enrollment in the trial [30][31] Question: Any updates on government funding from NIAID? - The company has received reassurance from NIAID regarding probable funding and expects to hear conclusively in June, indicating that NIAID has not been heavily impacted by recent delays [32][33] Question: Can the company provide details on the GVHD trial and patient enrollment? - The company plans to study GVHD in both steroid refractory acute patients and in prophylaxis settings, with discussions with regulators imminent [37][39]

Financial Data and Key Metrics Changes - Net sales for the quarter were $166 million, a decrease of $104 million or 39% compared to the prior year period, driven by a deliberate reduction of inventory and lower store count [17][18] - Gross profit for the quarter was $44 million, an increase of $6 million compared to the prior year period [18] - SG&A expenses improved to $39 million for the quarter compared to $49 million in the prior year period, primarily due to reduced overhead personnel and marketing expenses [18][19] - The company achieved a gross margin of 24% excluding LIFO adjustments, representing a 10% increase compared to the prior year [18] - Adjusted EBITDA loss was $4 million, an improvement compared to the loss of $18 million in the prior year period [19] Business Line Data and Key Metrics Changes - New unit sales were down 36% or 912 units in the quarter, while average selling price for new units was 15% better for the quarter [16] - Pre-owned retail unit sales were down 48% or 655 units during the quarter, reflective of divestitures [16] - Gross margins for new vehicles were 11% for the quarter, a 7% increase compared to the prior year period, while used vehicle gross margins were 21%, a 10% increase [17] Market Data and Key Metrics Changes - New inventory comprised of 82% model year 2025 and 2026 units, up significantly from last quarter [13] - The company noted a shift towards single axle towables and first-time buyers, with motorized inventory sales improving 11% in the first quarter versus the fourth quarter [13] Company Strategy and Development Direction - The company outlined a two-part strategy focused on optimizing dealership footprint and maximizing operational performance [5] - The sale of five dealerships to Camping World allowed the company to significantly deleverage its balance sheet by repaying approximately $145 million in debt [6] - The company entered into a letter of intent to divest three additional stores, aiming to refine its footprint and reinforce its financial position [7] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the RV lifestyle's affordability and consumer attraction despite potential tariff impacts [9] - The company is closely monitoring customer demand and macroeconomic trends, including tariffs and supply chain shortages [13] - Management remains committed to strengthening the balance sheet to support long-term growth and stability [20] Other Important Information - The company reported a loss from operations of $2.3 million for the quarter, which included non-cash impairment charges of $2.9 million [19] - The company reduced debt by $145 million during the quarter, contributing to meaningful deleveraging [19] Q&A Session Summary - No questions were fielded following the conclusion of prepared remarks, and the call concluded without a Q&A session [4]

Ondas (ONDS) Q1 2025 Earnings Call May 15, 2025 08:30 AM ET Speaker0 Welcome to the Ondus Holdings Inc. First Quarter twenty twenty five Conference Call. All participants will be in listen only mode. Before we begin, the company would like to remind you that this call may contain forward looking statements. While these forward looking statements reflect OnBase's best current judgment, they are subject to risks and uncertainties that could cause actual results to differ materially from those implied by these ...

Taysha Gene Therapies Inc (TSHA) Q1 2025 Earnings Call May 15, 2025 08:30 AM ET Speaker0 Greetings, and welcome to the Tatia Gene Therapies First Quarter twenty twenty five Earnings Call. At this time, all participants are in listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Hayley Collins, Director, Head of Corporate Communications. Please go ahead. Speaker1 Thank ...